The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system (Q34503796)

2 August 2017

14 references

13 March 2019

14 March 2019

24 March 2019

18 June 2019

19 June 2019

28 September 2019

2 October 2019

9 October 2019

17 November 2019

31 August 2020

18 November 2020

30 January 2021

4 February 2021

24 August 2022

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system (English)

1 reference

dipeptidyl peptidase-4 inhibitors

2 August 2017

8 references

28 September 2019

2 October 2019

9 October 2019

17 November 2019

29 May 2020

31 August 2020

18 November 2020

4 February 2021

1 reference

28 September 2019

1 reference

2 October 2019

1 reference

9 October 2019

1 reference

17 November 2019

5 references

31 August 2020

18 November 2020

30 January 2021

4 February 2021

24 August 2022

1 reference

18 November 2020

1 reference

30 January 2021

1 reference

30 January 2021

Guntram Schernthaner

1

1 reference

2 August 2017

Carl Erik Mogensen

series ordinal

2

1 reference

2 August 2017

Gerit-Holger Schernthaner

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 September 2014

16 references

Diabetes and Vascular Disease Research

2 August 2017

13 March 2019

14 March 2019

24 March 2019

18 June 2019

19 June 2019

28 September 2019

2 October 2019

9 October 2019

17 November 2019

29 May 2020

31 August 2020

18 November 2020

30 January 2021

4 February 2021

24 August 2022

15 references

2 August 2017

13 March 2019

14 March 2019

24 March 2019

18 June 2019

19 June 2019

28 September 2019

2 October 2019

9 October 2019

17 November 2019

31 August 2020

18 November 2020

30 January 2021

4 February 2021

24 August 2022

11

1 reference

2 August 2017

306-323

1 reference

2 August 2017

5

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

2 August 2017

14 references

13 March 2019

14 March 2019

24 March 2019

18 June 2019

19 June 2019

28 September 2019

2 October 2019

9 October 2019

17 November 2019

31 August 2020

18 November 2020

30 January 2021

4 February 2021

on focus list of Wikimedia project

24 August 2022

ScienceSource

0 references

cites work

Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Standards of medical care in diabetes--2013

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Sodium glucose cotransporter 2 and the diabetic kidney

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Cardiovascular biology of the incretin system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Limitations and future treatment options in type 2 diabetes with renal impairment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Monitoring kidney function and albuminuria in patients with diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Unraveling the science of incretin biology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

The pathogenesis of diabetic nephropathy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Prevalence of chronic kidney disease in population-based studies: systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Obesity, diabetes, and chronic kidney disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Statins for improving renal outcomes: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Renal Na(+)-glucose cotransporters

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Prevalence of chronic kidney disease in an urban Mexican population

7 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Estimating the prevalence of renal insufficiency in seniors requiring long-term care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Progression of kidney dysfunction in the community-dwelling elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Level of kidney function as a risk factor for cardiovascular outcomes in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Low glomerular filtration in the population: prevalence, associated disorders, and awareness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

International comparison of the relationship of chronic kidney disease prevalence and ESRD risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Prevalence of chronic kidney disease in a middle and old-aged population of Beijing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Renal function and cardiovascular risk markers in a remote Australian Aboriginal community

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

The association among smoking, heavy drinking, and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Screening for kidney disease in adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Prevalence of chronic kidney disease and associated risk factors--United States, 1999-2004.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230539

Continued Smoking Exacerbates but Cessation Ameliorates Progression of Early Type 2 Diabetic Nephropathy

27 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114542802

Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart Study

21 January 2018

1 reference

12 December 2020

Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study

1 reference

12 December 2020

Kidney disease in diabetology: lessons from 2010

1 reference

12 December 2020

Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control

1 reference

12 December 2020

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients

1 reference

12 December 2020

Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Identifiers

DOI

10.1177/1479164114542802

1 reference

2 August 2017

1 reference

2 August 2017

1 reference